Belatacept in kidney transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 6, 2012, Pages 640-647

  Wojciechowski, David ^a   Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

belatacept; costimulation; kidney transplant

Indexed keywords

ABATACEPT; BELATACEPT; CD28 ANTIGEN; CYCLOSPORIN;

ACUTE GRAFT REJECTION; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIGENS, CD28; CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84870251070     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835a4c0d     Document Type: Review

References (35)

1. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 1999; 96:185-190. (Pubitemid 29036074)
2. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002; 13:559-575. (Pubitemid 34106301)
3. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1:220-228. (Pubitemid 33741960)
4. + T cells. Immunol Rev 1998; 165:231-247. (Pubitemid 28524215)
5. Kim KS, Denton MD, Chandraker A, et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol 2001; 158:977-986. (Pubitemid 32221789)
6. Judge TA, Tang A, Spain LM, et al. The in vivo mechanism of action of CTLA4Ig. J Immunol 1996; 156:2294-2299. (Pubitemid 26087460)
7. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443-453. (Pubitemid 40313335)
8. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992; 257:789-792.
9. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation.; et al. Transplantation 2009; 87:926-933.
10. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114-1123. (Pubitemid 41317434)
11. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907-1915. (Pubitemid 37409707)
12. Stephens NATS. Successful long-term patient and renal allograft outcomes after abatacept conversion. Am J Transplant 2012; 12 (Suppl 3):300.
13. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with bela-tacept in renal transplantation. N Engl J Med 2005; 353:770-781. (Pubitemid 41215486)
14. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
15. Wojciechowski D, Vincenti F. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. Semin Immunol 2011; 23:157-64.
16. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12:210-217.
17. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90:1528-1535.
18. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
19. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12:630-639.
20. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91:976-983.
21. Holdas H, Holme I, Jardine A, et al. Cardiovascular Risk Calculator for Renal Transplant Recipients: Applications to BENEFIT and BENEFIT-EXT Trials. Am J Transplant 2012; 12 (Suppl 3):409.
22. Grinyo J, Alberu J, Contieri FL, et al. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. Transpl Int 2012.
23. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2011; 6:430-439.
24. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9:1063-1071.
25. Opelz G, Dohler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85:661-666. (Pubitemid 351398238)
26. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-714. (Pubitemid 36745243)
27. Tanaka T, Kyo M, Kokado Y, et al. Correlation betweenthe Banff97classification of renal allograft biopsies and clinical outcome. Transpl Int 2004; 17:59-64. (Pubitemid 38315867)
28. Vereerstraeten P, Abramowicz D, de Pauw L, Kinnaert P. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997; 63:1739-1743. (Pubitemid 27278944)
29. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003; 196:147-160. (Pubitemid 37468109)
30. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14:2402-2410. (Pubitemid 37052389)
31. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009; 229:271-293.
32. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8:2086-2096.
33. Bestard O, Cassis L, Cruzado JM, et al. Costimulatory blockade with mTOR inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int 2011; 24:451-460.
34. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90:1521-1527.
35. Administration. UFaD. FDA labeling information-Nulojix. 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125288s0000lbl.pdf. [Accessed 30 August 2012].